Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.

This study aims to figure out the worldwide prevalence of anticancer therapy-associated acute kidney injury (AKI) and tubulointerstitial nephritis (TIN) and the relative risk of each cancer drug. We conducted an analysis of VigiBase, the World Health Organization pharmacovigilance database, 1967-202...

ver descrição completa

Detalhes bibliográficos
Autores: Yoon SY, Lee S, Lee K, Kim JS, Hwang HS, Kronbichler A, Jacob L, Shin JY, Lee JA, Park J, Lee H, Jeong K, Yon DK
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p26531
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=26531
Access Level:acceso abierto
Palavra-chave:Acute kidney injury
Anticancer drugs
Tubulointerstitial nephritis
World Health Organization
id ES_3979262da0c807bf0e3fa9fa86f32f73
oai_identifier_str oai:fsjd.fundanetsuite.com:p26531
network_acronym_str ES
network_name_str España
repository_id_str
spelling Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.Yoon SYLee SLee KKim JSHwang HSKronbichler AJacob LShin JYLee JAPark JLee HLee HJeong KYon DKAcute kidney injuryAnticancer drugsTubulointerstitial nephritisWorld Health OrganizationThis study aims to figure out the worldwide prevalence of anticancer therapy-associated acute kidney injury (AKI) and tubulointerstitial nephritis (TIN) and the relative risk of each cancer drug. We conducted an analysis of VigiBase, the World Health Organization pharmacovigilance database, 1967-2023 via disproportionate Bayesian reporting method. We further categorized the anticancer drugs into four groups: cytotoxic therapy, hormone therapy, immunotherapy, and targeted therapy. Reporting odds ratio (ROR) and information component (IC) compares observed and expected values to investigate the associations of each category of anticancer drugs with AKI and TIN. We identified 32,722 and 2056 reports (male, n = 17,829 and 1,293) of anticancer therapy-associated AKI and TIN, respectively, among 4,592,036 reports of all-drug caused AKI and TIN. There has been a significant increase in reports since 2010, primarily due to increased reports of targeted therapy and immunotherapy. Immunotherapy exhibited a significant association with both AKI (ROR: 8.92; IC(0.25): 3.06) and TIN (21.74; 4.24), followed by cytotoxic therapy (7.14; 2.68), targeted therapy (5.83; 2.40), and hormone therapy (2.59; 1.24) for AKI, and by cytotoxic therapy (2.60; 1.21) and targeted therapy (1.54; 0.61) for TIN. AKI and TIN were more prevalent among individuals under 45 years of age, with a female preponderance for AKI and males for TIN. These events were reported in close temporal relationship after initiation of the respective drug (16.53 days for AKI and 27.97 days for TIN), and exhibited a high fatality rate, with 23.6% for AKI and 16.3% for TIN. These findings underscore that kidney-related adverse drug reactions are of prognostic significance and strategies to mitigate such side effects are required to optimize anticancer therapy.NATURE PORTFOLIO2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=26531Scientific ReportsISSN: 20452322reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p265312026-05-27T12:37:41Z
dc.title.none.fl_str_mv Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
title Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
spellingShingle Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
Yoon SY
Acute kidney injury
Anticancer drugs
Tubulointerstitial nephritis
World Health Organization
title_short Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
title_full Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
title_fullStr Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
title_full_unstemmed Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
title_sort Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
dc.creator.none.fl_str_mv Yoon SY
Lee S
Lee K
Kim JS
Hwang HS
Kronbichler A
Jacob L
Shin JY
Lee JA
Park J
Lee H
Lee H
Jeong K
Yon DK
author Yoon SY
author_facet Yoon SY
Lee S
Lee K
Kim JS
Hwang HS
Kronbichler A
Jacob L
Shin JY
Lee JA
Park J
Lee H
Jeong K
Yon DK
author_role author
author2 Lee S
Lee K
Kim JS
Hwang HS
Kronbichler A
Jacob L
Shin JY
Lee JA
Park J
Lee H
Jeong K
Yon DK
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Acute kidney injury
Anticancer drugs
Tubulointerstitial nephritis
World Health Organization
topic Acute kidney injury
Anticancer drugs
Tubulointerstitial nephritis
World Health Organization
description This study aims to figure out the worldwide prevalence of anticancer therapy-associated acute kidney injury (AKI) and tubulointerstitial nephritis (TIN) and the relative risk of each cancer drug. We conducted an analysis of VigiBase, the World Health Organization pharmacovigilance database, 1967-2023 via disproportionate Bayesian reporting method. We further categorized the anticancer drugs into four groups: cytotoxic therapy, hormone therapy, immunotherapy, and targeted therapy. Reporting odds ratio (ROR) and information component (IC) compares observed and expected values to investigate the associations of each category of anticancer drugs with AKI and TIN. We identified 32,722 and 2056 reports (male, n = 17,829 and 1,293) of anticancer therapy-associated AKI and TIN, respectively, among 4,592,036 reports of all-drug caused AKI and TIN. There has been a significant increase in reports since 2010, primarily due to increased reports of targeted therapy and immunotherapy. Immunotherapy exhibited a significant association with both AKI (ROR: 8.92; IC(0.25): 3.06) and TIN (21.74; 4.24), followed by cytotoxic therapy (7.14; 2.68), targeted therapy (5.83; 2.40), and hormone therapy (2.59; 1.24) for AKI, and by cytotoxic therapy (2.60; 1.21) and targeted therapy (1.54; 0.61) for TIN. AKI and TIN were more prevalent among individuals under 45 years of age, with a female preponderance for AKI and males for TIN. These events were reported in close temporal relationship after initiation of the respective drug (16.53 days for AKI and 27.97 days for TIN), and exhibited a high fatality rate, with 23.6% for AKI and 16.3% for TIN. These findings underscore that kidney-related adverse drug reactions are of prognostic significance and strategies to mitigate such side effects are required to optimize anticancer therapy.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=26531
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=26531
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv NATURE PORTFOLIO
publisher.none.fl_str_mv NATURE PORTFOLIO
dc.source.none.fl_str_mv Scientific Reports
ISSN: 20452322
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406166545596416
score 15.812429

Registos relacionados